Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Gruppo Italiano Malattie EMatologiche dell'Adulto clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy and Spain registers with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. Synced 21 Nov 2026
23Current trials
12Recruiting now
12Drugs in these trials
2Trial registers
At a glance

Gruppo Italiano Malattie EMatologiche dell'Adulto is the lead sponsor of 23 current clinical trials in our Italy and Spain registers. 12 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Ponatinib, Venetoclax and Asciminib. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

  • Recruiting1252%
  • Not yet open14%
  • Active, closed1043%

Trials by phase

  • Observational835%
  • Phase 2730%
  • Not applicable522%
  • Phase 3313%
01

Clinical trials sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto

23 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
NCT07080970 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, NPM1 Mutation
Observational Recruiting 2026-07 Italy
Biologic Characterization of Patients With ITP
NCT05694325 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia
Not applicable Recruiting 2023-11 Italy
Study on the Diagnosis and Management of CLL in Italy by GIMEMA
NCT04867915 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
Observational Recruiting 2021-10 Italy
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936 · ClinicalTrials.gov ↗ · CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive
Phase 2 Recruiting 2025-06 Spain
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
NCT07912684 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma
Not applicable Recruiting 2026-11 Italy
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
NCT05694312 · ClinicalTrials.gov ↗ · Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Drug: Ibrutinib
Phase 2 Recruiting 2023-11 Italy
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 3 Recruiting 2020-09 Italy
Novel Approaches to Target MECOM/EVI1 in AML
NCT05839392 · ClinicalTrials.gov ↗ · AML, Adult
Not applicable Recruiting 2023-12 Italy
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
NCT06028087 · ClinicalTrials.gov ↗ · Multiple Myeloma, Diagnosis
Observational Recruiting 2025-03 Italy
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
NCT06513273 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, AML, Adult, Acute Myeloid Leukemia, Adult
Observational Recruiting 2025-07 Italy
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
NCT04184505 · ClinicalTrials.gov ↗ · High-risk MDS
Phase 3 Recruiting 2020-11 Italy
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
NCT06933277 · ClinicalTrials.gov ↗ · Multiple Myeloma
Observational Recruiting 2025-08 Italy
Biological and Clinical Efficacy of Shingrix in Patients With CLL
NCT06364033 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL
Not applicable Not yet open 2024-08 Italy
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax
NCT04763928 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 2 Active, closed 2021-12 Italy
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
NCT06253637 · ClinicalTrials.gov ↗ · T-Lymphocytic Leukemia, Acute
Phase 2 Active, closed 2024-10 Italy
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
Phase 3 Active, closed 2021-09 Italy
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438 · ClinicalTrials.gov ↗ · Acute Lymphoid Leukemia
Phase 2 Active, closed 2019-10 Italy
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches
NCT04460963 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Not applicable Active, closed 2021-06 Italy
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512 · ClinicalTrials.gov ↗ · High Risk CLL, Chronic Lymphocytic Leukemia
Phase 2 Active, closed 2023-07 Italy
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05306301 · ClinicalTrials.gov ↗ · Chemotherapy, Leukemia, Acute Lymphoblastic
Drug: Ponatinib
Phase 2 Active, closed 2022-10 Italy
Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma
NCT03190525 · ClinicalTrials.gov ↗ · Multiple Myeloma
Observational Active, closed 2017-11 Italy
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
NCT04282811 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
Observational Active, closed 2020-07 Italy
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
NCT04378855 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasm
Observational Active, closed 2020-05 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Gruppo Italiano Malattie EMatologiche dell'Adulto trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Gruppo Italiano Malattie EMatologiche dell'Adulto trials

31 conditions
Acute Myeloid Leukemia6Chronic Lymphocytic Leukemia5Multiple Myeloma4Small Lymphocytic Lymphoma3AML, Adult2CML, Chronic Phase1Chronic Myeloid Leukemia, Chronic Phase1Chronic Myeloid Leukemia, BCR/ABL-Positive1Chronic Myeloid Leukemia1NPM1 Mutation1Immune Thrombocytopenia1T-Lymphocytic Leukemia, Acute1Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)1ALL, Adult1Philadelphia-Positive ALL1Acute Lymphoid Leukemia1MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type1Lymphoma1CLL-like MBL1Varicella-zoster Virus Reactivation1Autoimmune Hemolytic Anemia1Monoclonal B-Cell Lymphocytosis CLL-Type1High Risk CLL1Chemotherapy1
06

Questions about Gruppo Italiano Malattie EMatologiche dell'Adulto trials

How many clinical trials does Gruppo Italiano Malattie EMatologiche dell'Adulto sponsor?

Gruppo Italiano Malattie EMatologiche dell'Adulto is the lead sponsor of 23 current trials on ClinicalTrials.gov in our Italy and Spain registers, as of the registry sync on 21 November 2026. Completed and withdrawn studies are not counted.

Are Gruppo Italiano Malattie EMatologiche dell'Adulto trials recruiting?

Yes. 12 of its 23 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Gruppo Italiano Malattie EMatologiche dell'Adulto testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Ponatinib (2), Venetoclax (2), Asciminib (1), Azacitidine (1) and Blinatumomab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.